by Katie Hogan | Jul 29, 2026 | Market Access
| Author: Alison Kneen, Global Market Access Practice Lead, BioVid The timeline between clinical development and commercial launch is shrinking. Not because science is moving faster, but because regulators, HTA bodies, and market access expectations are becoming...
by Katie Hogan | Jun 18, 2026 | Oncology
As we head to Chicago for ASCO 2026, the most critical questions go beyond which trials met their primary endpoints. They are about what happens next in the clinic, in the market, and in the minds of the physicians who must translate this data into practice. Here are...
by Katie Hogan | Jun 11, 2026 | Insights
Author: Gregg Quy, Senior Director, Insights & Strategy There is a famous story about Michelangelo. Asked how he created such transcendent sculpture, he replied simply: “I saw the angel in the marble and carved until I set him free.” The masterpiece...
by Katie Hogan | Jun 4, 2026 | AI
A recent Wharton experiment found that AI assistance can hurt users substantially when the AI is wrong. When AI gave correct answers, AI-assisted users outperformed an unassisted control. When AI gave wrong answers, AI-assisted users performed substantially worse than...
by Katie Hogan | May 19, 2026 | Market Access
| Author: Alison Kneen, Global Market Access Practice Lead, BioVid Geopolitics is crucial to understand in today’s pharmaceutical market. This week saw the White House claim that their Most Favored Nation (MFN) policy was going to create potential savings of $529...
